Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David S Ritchie

Showing results (71-80 of 91) with videos related to

Pageof 10
Sort By:
Blood Advances|January 24, 2025
Nivolumab and rituximab in treatment-naïve follicular lymphoma: the phase 2 1st FLOR studyAllison Barraclough, Sze Ting Lee, Melinda Burgess, et al.
Annals of Hematology|March 6, 2014
Limited clinical benefit for surveillance PET-CT scanning in patients with histologically transformed lymphoma in complete metabolic remission following primary therapyChan Y Cheah, Michael Dickinson, Michael S Hofman, et al.
Bone Marrow Transplantation|April 23, 2026
Pre-transplant azacitidine does not improve survival in allogeneic HSCT for higher-risk MDSMiles Horton, Becky Leung, Ricky Nelles, et al.
The Journal of Clinical Investigation|June 16, 2015
Immunosurveillance and therapy of multiple myeloma are CD226 dependentCamille Guillerey, Lucas Ferrari de Andrade, Slavica Vuckovic, et al.
Clinical & Translational Immunology|December 2, 2024
Choice of activation protocol impacts the yield and quality of CAR T cell product, particularly with older individualsPalak H Mehta, Gemma S Trollope, Patrick Leung, et al.
Leukemia & Lymphoma|April 15, 2014
The utility and limitations of (18)F-fluorodeoxyglucose positron emission tomography with computed tomography in patients with primary mediastinal B-cell lymphoma: single institution experience and literature reviewChan Y Cheah, Michael S Hofman, John F Seymour, et al.
British Journal of Haematology|March 28, 2019
Lenalidomide maintenance treatment after imatinib discontinuation: results of a phase 1 clinical trial in chronic myeloid leukaemiaDavid M Ross, Ilaria S Pagani, Yazad D Irani, et al.
Cell Death and Differentiation|November 14, 2018
Recipient BCL2 inhibition and NK cell ablation form part of a reduced intensity conditioning regime that improves allo-bone marrow transplantation outcomesYuhao Jiao, Joanne E Davis, Jai Rautela, et al.
The Journal of Clinical Investigation|April 21, 2015
Immunosurveillance and therapy of multiple myeloma are CD226 dependentCamille Guillerey, Lucas Ferrari de Andrade, Slavica Vuckovic, et al.
Oncoimmunology|September 26, 2015
Induction of potent NK cell-dependent anti-myeloma cytotoxic T cells in response to combined mapatumumab and bortezomibPaul J Neeson, Andy K Hsu, Yin R Chen, et al.
Pageof 10

Showing results (71-80 of 91) with videos related to

Sort By:
Pageof 10
Blood Advances|January 24, 2025
Nivolumab and rituximab in treatment-naïve follicular lymphoma: the phase 2 1st FLOR studyAllison Barraclough, Sze Ting Lee, Melinda Burgess, et al.
Annals of Hematology|March 6, 2014
Limited clinical benefit for surveillance PET-CT scanning in patients with histologically transformed lymphoma in complete metabolic remission following primary therapyChan Y Cheah, Michael Dickinson, Michael S Hofman, et al.
Bone Marrow Transplantation|April 23, 2026
Pre-transplant azacitidine does not improve survival in allogeneic HSCT for higher-risk MDSMiles Horton, Becky Leung, Ricky Nelles, et al.
The Journal of Clinical Investigation|June 16, 2015
Immunosurveillance and therapy of multiple myeloma are CD226 dependentCamille Guillerey, Lucas Ferrari de Andrade, Slavica Vuckovic, et al.
Clinical & Translational Immunology|December 2, 2024
Choice of activation protocol impacts the yield and quality of CAR T cell product, particularly with older individualsPalak H Mehta, Gemma S Trollope, Patrick Leung, et al.
Leukemia & Lymphoma|April 15, 2014
The utility and limitations of (18)F-fluorodeoxyglucose positron emission tomography with computed tomography in patients with primary mediastinal B-cell lymphoma: single institution experience and literature reviewChan Y Cheah, Michael S Hofman, John F Seymour, et al.
British Journal of Haematology|March 28, 2019
Lenalidomide maintenance treatment after imatinib discontinuation: results of a phase 1 clinical trial in chronic myeloid leukaemiaDavid M Ross, Ilaria S Pagani, Yazad D Irani, et al.
Cell Death and Differentiation|November 14, 2018
Recipient BCL2 inhibition and NK cell ablation form part of a reduced intensity conditioning regime that improves allo-bone marrow transplantation outcomesYuhao Jiao, Joanne E Davis, Jai Rautela, et al.
The Journal of Clinical Investigation|April 21, 2015
Immunosurveillance and therapy of multiple myeloma are CD226 dependentCamille Guillerey, Lucas Ferrari de Andrade, Slavica Vuckovic, et al.
Oncoimmunology|September 26, 2015
Induction of potent NK cell-dependent anti-myeloma cytotoxic T cells in response to combined mapatumumab and bortezomibPaul J Neeson, Andy K Hsu, Yin R Chen, et al.
Pageof 10